Anna K Forbes, William Hinton, Michael D Feher, William Elson, José M Ordóñez-Mena, Mark Joy, Xuejuan Fan, Debasish Banerjee, Nicholas I Cole, Neil Munro, Martin Whyte, Rebecca J Suckling, Pauline A Swift, Simon de Lusignan
BACKGROUND/HYPOTHESIS: Observational studies suggest sodium-glucose co-transporter-2 (SGLT2) inhibitor kidney outcome trials are not representative of the broader population of people with chronic kidney disease (CKD). However, there are limited data on the generalisability to those without co-existing type 2 diabetes (T2D), and the representativeness of the EMPA-KIDNEY trial has not been adequately explored. We hypothesised that SGLT2 inhibitor kidney outcome trials are more representative of people with co-existing T2D than those without, and that EMPA-KIDNEY is more representative than previous trials...
March 22, 2024: Nephrology, Dialysis, Transplantation